You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

VASOPRESSIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Vasopressin, and when can generic versions of Vasopressin launch?

Vasopressin is a drug marketed by Am Regent, Amneal, Amphastar Pharms Inc, Cipla, Dr Reddys, Eagle Pharms, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Baxter Hlthcare Corp, and Long Grove Pharms. and is included in eleven NDAs.

The generic ingredient in VASOPRESSIN is vasopressin. There are nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the vasopressin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vasopressin

A generic version of VASOPRESSIN was approved as vasopressin by AM REGENT on August 3rd, 2020.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VASOPRESSIN?
  • What are the global sales for VASOPRESSIN?
  • What is Average Wholesale Price for VASOPRESSIN?
Drug patent expirations by year for VASOPRESSIN
Drug Prices for VASOPRESSIN

See drug prices for VASOPRESSIN

Recent Clinical Trials for VASOPRESSIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Hospital, Basel, SwitzerlandPhase 2
Kingman Regional Medical CenterPhase 4
University of AlbertaPhase 1

See all VASOPRESSIN clinical trials

Pharmacology for VASOPRESSIN
Physiological EffectDecreased Diuresis
Vasoconstriction
Paragraph IV (Patent) Challenges for VASOPRESSIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VASOSTRICT Injection vasopressin 20 units/100 mL 204485 1 2022-12-20
VASOSTRICT Injection vasopressin 40 units/100 mL and 60 units/100 mL 204485 1 2022-02-28
VASOSTRICT Injection vasopressin 200 units/10 mL 204485 1 2018-06-29
VASOSTRICT Injection vasopressin 20 units/mL, 1 mL 204485 1 2018-03-23

US Patents and Regulatory Information for VASOPRESSIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Am Regent VASOPRESSIN vasopressin SOLUTION;INTRAVENOUS 212593-001 Aug 3, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eagle Pharms VASOPRESSIN vasopressin SOLUTION;INTRAVENOUS 211538-001 Dec 15, 2021 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amphastar Pharms Inc VASOPRESSIN vasopressin SOLUTION;INTRAVENOUS 211857-001 Jul 18, 2022 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare Corp VASOPRESSIN IN SODIUM CHLORIDE 0.9% vasopressin SOLUTION;INTRAVENOUS 217569-002 Sep 29, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.